Invention Grant
- Patent Title: Tumor targeted drug combretastatin A4 derivative
- Patent Title (中): 肿瘤靶向药物考布他汀A4衍生物
-
Application No.: US14127847Application Date: 2012-07-04
-
Publication No.: US09139574B2Publication Date: 2015-09-22
- Inventor: Yong Wang , Cang Zhang , Xiaorong Liu , Yan Zhang , Yunyun Wang , Wenping Zhang
- Applicant: Yong Wang , Cang Zhang , Xiaorong Liu , Yan Zhang , Yunyun Wang , Wenping Zhang
- Applicant Address: CN Nanjing
- Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.
- Current Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Nanjing
- Agency: Fox Rothschild LLP
- Agent Wansheng Jerry Liu
- Priority: CN201110186688 20110705; CN201110422678 20111216
- International Application: PCT/CN2012/000921 WO 20120704
- International Announcement: WO2013/004075 WO 20130110
- Main IPC: C07D413/04
- IPC: C07D413/04 ; C07D233/64 ; C07D263/32 ; C07D277/24 ; C07C251/24 ; C07D277/22 ; A61K31/53
Abstract:
The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.
Public/Granted literature
- US20140128384A1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE Public/Granted day:2014-05-08
Information query
